

Standard Control with Advanced Control Specialty Formulary[®]

April 2025 Updates

Removals	Additions
4	3

Formulary Removals

Drug Class	Removed Product(s)	Formulary Options
Antineoplastic Agents, Kinase Inhibitors*	COTELLIC	MEKINIST, MEKTOVI
	SPRYCEL**	dasatinib, imatinib mesylate, BOSULIF, SCEMBLIX
	ZELBORAF	BRAFTOVI, TAFINLAR
Central Nervous System, Antidepressants*	FLUOXETINE TABLET 60MG	citalopram, escitalopram, fluoxetine (except fluoxetine tablet 60 mg, fluoxetine tablet [generics for SARAFEM]), paroxetine HCl, paroxetine HCl ext-rel (except NDC 60505367503), sertraline, vilazodone, TRINTELLIX

Formulary Additions

Drug Class	Product(s) Added
Antineoplastic Agents, Kinase Inhibitors*	MEKINIST TABLETS, TAFINLAR CAPSULES
Autoimmune Agents, Self-Administered*	ADALIMUMAB-FKJP^

Indication-Based Strategy Updates

Drug Class	Target Product(s)	Formulary Options
Autoimmune Agents, Self-Administered, Hidradenitis Suppurativa [†]	AMJEVITA, HUMIRA	ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, COSENTYX SUBCUTANEOUS, HYRIMOZ

*Class has existing formulary exclusions **Multi-source Brand Product ^Product under New to Market review since launch and will be added to formulary. [†]New Indication-Based category. This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of January 31, 2025 and subject to change.